AHPBA Sponsored Consensus Conference on the

Multidisciplinary
Treatment of
Bile Duct Cancer
Wednesday, January 15, 2014
S...
Multidisciplinary Treatment of Bile Duct Cancer (BDC)
Wednesday, January 15, 2014	 San Francisco Marriott Marquis
	

55 Fo...
Program Planning Committee

Program
Wednesday, January 15, 2014

Thomas A. Aloia, MD, Co-Chair
The University of Texas
MD ...
10:30a.m.–12:30 p.m.	 SESSION II: INTRAHEPATIC CHOLANGIOCARCINOMA (IHCCA)
	
Moderators: Masaru Miyazaki, MD; Sharon M. Web...
Faculty

Registration Information

Ghassan K. Abou-Alfa, MD
Memorial Sloan-Kettering Cancer Center
Weill Medical College a...
(must provide letter from Director)

1 Trainees...................................... $125.00
IDT Approver E-mail

1 Postm...
Department of CME/Conference Management - Unit 1381
The University of Texas MD Anderson Cancer Center
# 176700/110845/3007...
Upcoming SlideShare
Loading in …5
×

AHPBA Sponsored Consensus Conference on the Multidisciplinary Treatment of Bile Duct Cancer

308 views

Published on

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
308
On SlideShare
0
From Embeds
0
Number of Embeds
7
Actions
Shares
0
Downloads
2
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

AHPBA Sponsored Consensus Conference on the Multidisciplinary Treatment of Bile Duct Cancer

  1. 1. AHPBA Sponsored Consensus Conference on the Multidisciplinary Treatment of Bile Duct Cancer Wednesday, January 15, 2014 San Francisco Marriott Marquis 55 Fourth Street San Francisco, California
  2. 2. Multidisciplinary Treatment of Bile Duct Cancer (BDC) Wednesday, January 15, 2014 San Francisco Marriott Marquis 55 Fourth Street • San Francisco, California Goal The focus of this consensus conference is the multidisciplinary management of patients with bile duct cancers. The aim of this conference is to review the current indications for surgical treatment, non-surgical interventions, and adjuvant therapy for bile duct cancer. This topic has not previously been discussed in a consensus conference format, and therefore, there is likely to be a high education yield for participants. The format will divide the conference into three sessions, individually focusing on Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer. The program features an expert multispecialty international group of speakers, panelists, and moderators with extensive experience in the diagnosis, staging, treatment, and research related to the state-ofthe-art treatment of patients with bile duct malignancy. The goal of this meeting is to provide a forum to review, discuss, and establish current practice guidelines and consensus statements. At the conclusion of the conference, attendees should leave with a higher level of understanding and competence in the diagnosis and management of these disorders. * Not an official event of the 2014 Gastrointestinal Cancers Symposium. Not sponsored or endorsed by any of the co-sponsoring organizations of the 2014 Gastrointestinal Cancers Symposium. Educational Objectives After attending the conference, participants should be able to - Appropriately apply diagnostic and staging modalities to bile duct cancer patients (Knowledge, Competence, Performance); - Appropriately select the proper surgical treatment modalities available for the management of bile duct cancer (Knowledge, Competence, Performance); - Appropriately select and sequence the best multiple interventional and nonsurgical treatment modalities available for optimal management of bile duct cancer (Knowledge, Competence, Performance, Patient Outcomes); - Appropriately implement the most up-to-date systemic cytotoxic and biologic strategies in the management of bile duct cancer to improve patient outcomes (Knowledge, Competence, Performance, Patient Outcomes). Target Audience This conference will be beneficial to surgical oncologists, medical oncologists, radiologists, and interventional radiologists. Educational Methods Lectures – Question and Answer – Panel Discussions – Videos Evaluation A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvements activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics. Accreditation/Credit Designation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and The Americas Hepato-Pancreato-Biliary Association. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians. The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 7.50 AMA/PRA Category 1 Credits TM . Physicians should only claim the credit commensurate with the extent of their participation in the activity. CME Certificates and Attendance Verification Certificates Certificates awarding AMA/PRA Category 1 Credit TM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form. Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.
  3. 3. Program Planning Committee Program Wednesday, January 15, 2014 Thomas A. Aloia, MD, Co-Chair The University of Texas MD Anderson Cancer Center Houston, Texas Nipun B. Merchant, MD Vanderbilt University Medical Center Nashville, Tennessee John C. Mansour, MD, Co-Chair The University of Texas Southwestern Medical Center Dallas, Texas Carl R. Schmidt, MD The Ohio State University Columbus, Ohio 7:50–8:00 Introduction William C. Chapman, MD Sharon M. Weber, MD, Co-Chair University of Wisconsin Madison, Wisconsin Jean-Nicolas Vauthey, MD The University of Texas MD Anderson Cancer Center Houston, Texas 8:00–10:30 Eren Berber, MD Cleveland Clinic Cleveland, Ohio Theodore H. Welling, III, MD University of Michigan Ann Arbor, Michigan SESSION I: GALLBLADDER CANCER Moderators: Felipe José Fernández Coimbra, MD; William R. Jarnagin, MD Panelists: Rachna T. Shroff, MD; Elijah Dixon, MD; Jennifer Knox, MD William C. Chapman, MD Washington University School of Medicine St. Louis, Missouri Adam Yopp, MD University of Texas Southwestern Medical Center Dallas, Texas Alessandro Landskron Diniz, MD AC Camargo Cancer Center Sao Paulo, Brazil George Zogopoulos, MD, PhD McGill University Montreal, Quebec Canada Cristina R. Ferrone, MD Massachusetts General Hospital Boston, Massachusetts William Hawkins, MD Washington University School of Medicine St. Louis, Missouri Jill Kawulok AHPBA Leawood, Kansas Nonie Lowry AHPBA Leawood, Kansas William R. Jarnagin, MD Memorial Sloan-Kettering Cancer Center New York, New York Brigitte M. Taylor, CAP The University of Texas MD Anderson Cancer Center Houston, Texas Byrne Lee, MD City of Hope Duarte, California Constance C. Tierney, CMP The University of Texas MD Anderson Cancer Center Houston, Texas Shishir K. Maithel, MD Emory University Atlanta, Georgia 7:00–7:50 a.m. Continental Breakfast/Registration Pathologic Evaluation for Patients With Gallbladder Polyps and Suspicion of Early Stage Gallbladder Cancer Juan Carlos Roa, MD, MSc 8:20–8:30 Discussion 8:30–8:50 Evaluation and Management of the Patient Presenting With a Gallbladder Mass Nicolas Járufe Casis, MD 8:50–9:00 Discussion 9:00–9:20 Incidentally Discovered Gallbladder Cancer: The Gallbladder is Out, Now What Do We Do? Shishir K. Maithel, MD 9:20–9:30 Discussion 9:30–9:50 Advances in Neoadjuvant and Adjuvant Chemotherapy and Radiation Approaches to Gallbladder Cancer Milind Javle, MD 9:50–10:00 Discussion 8:00–8:20 10:00-10:30 Break
  4. 4. 10:30a.m.–12:30 p.m. SESSION II: INTRAHEPATIC CHOLANGIOCARCINOMA (IHCCA) Moderators: Masaru Miyazaki, MD; Sharon M. Weber, MD Panelists: Ghassan K. Abou-Alfa, MD; Michael A. Choti, MD, MBA; Michael I. D’Agelica, MD; Jeff Geschwind, MD 10:30–10:50 Recommendations for Diagnosis and Staging of IHCCA Timothy M. Pawlik, MD, MPH, PhD 10:50–11:00 Discussion 11:00–11:20 Local-Regional Treatment Strategies for IHCCA Dario Ribero, MD 11:20–11:30 Discussion 11:30–11:50 Hepatocholangiocarcinoma: Defining and Treating An Emerging Entity Norihiro Kokudo, MD, PhD 11:50–Noon Discussion Noon–12:20 Chemotherapy and Radiation Therapy for IHCCA Eileen M. O’Reilly, MD 12:20–12:30 p.m. Discussion 12:30–1:30 Lunch at the Movies: Case Presentations With Video Moderators: David M. Nagorney, MD; Paul D. Greig, MD Invited Presenters: Thomas A. Aloia, MD; Julie K. Heimbach, MD; William R. Jarnagin, MD; Nicolas Járufe Casis, MD; Norihiro Kokudo, MD, PhD; Masaru Miyazaki, MD; Masato Nagino, MD 1:30–3:30 SESSION III: HILAR CHOLANGIOCARCINOMA Moderators: John C. Mansour, MD; Jean-Nicolas Vauthey, MD Panelists: Alessandro Landskron Diniz, MD; Christopher E. Forsmark, MD Andrew X. Zhu, MD, PhD 1:30–1:50 Multimodality Evaluation of Patients With Suspected Hilar Cholangiocarcinoma: Including When to Proceed Without a Tissue Diagnosis Thomas A. Aloia, MD 1:50–2:00 Discussion 2:00–2:20 Transplantation for Hilar Cholangiocarcinoma With and Without PSC Julie K. Heimbach, MD 2:20–2:30 Discussion 2:30–2:50 Resectional Strategies for Hilar Cholangiocarcinoma Including Vascular Resection and the Concept of ‘No-Touch’ Masato Nagino, MD 2:50–3:00 Discussion 3:00–3:20 Traditional and Novel Chemotherapy and Radiation Approaches to Hilar Cholangiocarcinoma Christopher Crane, MD 3:20–3:30 Discussion 3:30–3:40 p.m Closing Comments Sharon M. Weber, MD
  5. 5. Faculty Registration Information Ghassan K. Abou-Alfa, MD Memorial Sloan-Kettering Cancer Center Weill Medical College at Cornell University New York, New York Jennifer Knox, MD, MSc University of Toronto Princess Margaret Toronto, Ontario, Canada On-site registration opens at 7:00 a.m. on Wednesday, January 15, 2014 at the San Francisco Marriott Marquis. The opening session of the conference will begin at 7:50 a.m. and the conference will adjourn at 3:40 p.m. on Wednesday, January 15, 2014. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees. Thomas A. Aloia, MD The University of Texas MD Anderson Cancer Center Houston, Texas Norihiro Kokudo, MD, PhD University of Tokyo Graduate School of Medicine Tokyo, Japan The deadline for advance registration is January 6, 2014. William C. Chapman, MD Washington University School of Medicine St. Louis, Missouri Michael A. Choti, MD, MBA University of Texas Southwestern Dallas, Texas Felipe José Fernández Coimbra, MD AC Camargo Hospital Sao Paulo, Brazil Christopher Crane, MD The University of Texas MD Anderson Cancer Center Houston, Texas Michael I. D’Angelica, MD Memorial Sloan-Kettering Cancer Hospital New York, New York Alessandro Landskron Diniz, MD AC Camargo Cancer Center Sao Paulo, Brazil Elijah Dixon, MD University of Calgary Calgary, Alberta, Canada Christopher E. Forsmark, MD University of Florida College of Medicine Gainesville, Florida Jeff Geschwind, MD Johns Hopkins University School of Medicine Baltimore, Maryland Paul D. Greig, MD University of Toronto Toronto, Ontario, Canada Julie K. Heimbach, MD Mayo Clinic Rochester, Minnesota William R. Jarnagin, MD Memorial Sloan-Kettering Cancer Center New York, New York Nicolas Járufe Casis, MD Pontificia Unversidad Catolica de Chile Santiago, Chile Milind Javle, MD The University of Texas MD Anderson Cancer Center Houston, Texas Shishir K. Maithel, MD Emory University Atlanta, Georgia John C. Mansour, MD University of Texas Southwestern Medical Center Dallas, Texas Masaru Miyazaki, MD Chiba University Graduate School of Medicine Chiba, Japan Masato Nagino, MD, PhD Nagoya University Graduate School of Medicine Nagoya, Japan David M. Nagorney, MD Mayo Clinic College of Medicine Rochester, Minnesota Eileen M. O’Reilly, MD Memorial Sloan-Kettering Cancer Center New York, New York Timothy M. Pawlik, MD, MPH, PhD Johns Hopkins Hospital Baltimore, Maryland Dario Ribero, MD Ospedale Ordine Mauriziano “Umberto I” Torino, Italy Juan Carlos Roa, MD, MSc Pontificia Universidad Catolica de Chile Santiago, Chile Rachna T. Shroff, MD The University of Texas MD Anderson Cancer Center Houston, Texas Jean-Nicolas Vauthey, MD The University of Texas MD Anderson Cancer Center Houston, Texas Sharon M. Weber, MD University of Wisconsin Madison, Wisconsin Andrew X. Zhu, MD, PhD Massachusetts General Hospital Harvard Medical School Boston, Massachusetts There are three ways to register: • Mail to: CME/Conference Management – Unit 1381, The University of Texas MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439 • Fax to: 713-794-1724 • On-line at www.mdanderson.org/conferences We accept the following forms of payment: • Check (payable through U.S. banks only) • Money Order • Credit Cards (MasterCard, VISA, and American Express) • Cash (on-site registration) A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee. The full conference registration fee includes the tuition, abstract book, breaks, and lunch. Refund/Cancellation Policy: The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 6, 2014. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866. The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified either by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee. The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. For additional information, contact CME/Conference Management at 713-792-2223 or 866-849-5866.
  6. 6. (must provide letter from Director) 1 Trainees...................................... $125.00 IDT Approver E-mail 1 Postmarked after 1/07/14........ $ 300.00 MD Anderson Employee ID No. (REQUIRED) 1 Postmarked by 1/07/14............. $ 260.00 Fund Type Fund IDT Approver Name (First/Last) please print Authorized Signature REQUIRED for credit card or IDT Fund Group* Department Business Unit Credit Card Number Credit Card Holder Name (First/Last) Phone (with area code) Emergency Contact E-mail Address (please print) MD Anderson Interdepartmental Transfer (IDT) No.: *Fund Group 90 will not be accepted Expiration Date Charge the following: oVISA oMasterCard oAmerican Express Credit Card Holder Billing Address & ZIP Code Fax (with area code) Cell Phone (with area code) Daytime Phone (with area code) City Street FULL CONFERENCE REGISTRATION FEE Department of CME/Conference Management – Unit 1381 The University of Texas MD Anderson Cancer Center PO Box 301439, Houston, TX 77230-1439 or fax to 713-794-1724 Make check or money order payable to: The University of Texas MD Anderson Cancer Center oNo oYes Physician State/Foreign Country/Zip or Mail Code ADDRESS TO: Institution Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/ Conference Management. All responses will be forwarded to the Program Chair for consideration. Specialty Photographing, audio taping and videotaping are prohibited. Department (include box no.) Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth. AHPBA Sponsored Consensus Conference on the Multidisciplinary Treatment of Bile Duct Cancer - January 15, 2014 The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity. CONFERENCE REGISTRATION - 0638/110845/30070638 The hotel is approximately 14 miles from San Francisco International Airport and 20 miles from the Oakland Airport. Taxis are available at the approximate price of $40 one way from SFO and $60 one way from Oakland. Super Shuttle is also available. Please call 415-558-8500 or book on line at www.supershuttle.com. MI Ground Transportation First If you are attending the 2014 Gastrointestinal Cancers Symposium, hotel rooms are available at the San Francisco Marriott Marquis, 55 Fourth Street, San Francisco, California. Reserve a room through the Symposium website at gicasym.org. Last Name Accommodations Highest Degree THIS IS NOT A SELF-MAILER Contact the Department of CME/Conference Management at 713-792-2223 or 866-849-5866 if you have any special dietary or ADA accommodation needs. AHPBA Sponsored Consensus Conference on the Multidisciplinary Treatment of Bile Duct Cancer Special Assistance
  7. 7. Department of CME/Conference Management - Unit 1381 The University of Texas MD Anderson Cancer Center # 176700/110845/30070638 PO Box 301439 Houston, TX 77230-1439 Non-Profit Org. U.S. Postage PAID Houston, TX Permit No. 7052

×